Welcome to our dedicated page for Remegen news (Ticker: REGMY), a resource for investors and traders seeking the latest updates and insights on Remegen stock.
RemeGen Co., Ltd. (REGMY) is a global biotechnology innovator developing advanced therapies for autoimmune disorders and oncology. This page aggregates official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find curated news about RemeGen's fusion protein therapies and antibody-drug conjugates (ADCs), including regulatory milestones for candidates like telitacicept and Disitamab Vedotin. Content spans trial phase results, partnership agreements, and market expansion initiatives.
Key updates include progress on B-cell modulation therapies for autoimmune conditions and targeted ADC treatments for solid tumors. All information is sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to RemeGen's latest developments in precision medicine and biopharmaceutical innovation. Check regularly for updates on therapies addressing primary Sjögren's syndrome, myasthenia gravis, and HER2-expressing cancers.
RemeGen showcased significant research results at the ASCO 2024 Annual Meeting in Chicago, held from May 31 to June 4, 2024. The company highlighted its innovative antibody drug conjugates (ADCs), Disitamab Vedotin (RC48) and RC88, through various presentations. This included one Clinical Science Symposium, five Poster presentations, and ten online Abstracts covering multiple cancer types such as gastric, bladder, and gynecological tumors.
Key presentations featured:
1. A Phase II trial on Disitamab Vedotin combined with Toripalimab and oral fluoropyrimidine S-1 for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma.
2. A Phase II study on neoadjuvant treatment with Disitamab Vedotin plus Toripalimab in muscle-invasive bladder cancer (MIBC), showing promising anti-tumor activity and manageable safety profiles.
Additional studies included Disitamab Vedotin for high-risk non-muscle invasive bladder cancer and advanced penile cancer, along with ten other abstracts on bladder, breast, and GI cancers.
RemeGen presented results from a Phase I/II clinical study of RC88, an antibody-drug conjugate targeting mesothelin (MSLN) in advanced solid tumors. The study included 170 patients with ovarian cancer, non-squamous non-small cell lung cancer, and cervical cancer who had failed standard therapies.
Key findings include:
- Ovarian cancer cohort: 45.2% overall response rate (ORR) and a median duration of response (DoR) of 8.02 months.
- Non-squamous non-small cell lung cancer cohort: 31.3% ORR and a median progression-free survival (PFS) of 6.87 months.
- Cervical cancer cohort: 33.3% ORR with a median DoR of 9.13 months.
These promising results suggest RC88's potential in improving outcomes for MSLN-expressing tumors.
RemeGen has announced the completion of patient enrollment for two Phase III clinical trials in China using Telitacicept for IgA nephropathy and primary Sjögren's syndrome (pSS). The trials enrolled 318 and 381 patients, respectively, aiming to evaluate the efficacy and safety of Telitacicept. The IgA nephropathy trial focuses on patients at risk of end-stage kidney disease, using pre-filled injections to simplify administration. The pSS trial measures changes in the EULAR Sjögren's syndrome disease activity index (ESSDAI) at week 24. These trials mark significant progress in RemeGen's efforts to provide more effective treatment options.
RemeGen Co. is celebrating World Lupus Day 2024 by sharing updates on its revolutionary fusion protein drug Telitacicept, offering hope to systemic lupus erythematosus (SLE) patients worldwide. Telitacicept, the world's first approved dual-target new fusion protein drug, has shown significant efficacy in treating SLE, offering a breakthrough in the global treatment of the disease. RemeGen's commitment to raising awareness about lupus and improving treatments underscores its mission to change the lives of millions affected by this autoimmune disease.
